Mon, October 30, 2017

Derek Archila Maintained (VNDA) at Buy with Increased Target to $26 on, Oct 30th, 2017

Derek Archila of Oppenheimer, Maintained "Vanda Pharmaceuticals Inc." (VNDA) at Buy with Increased Target from $21 to $26 on, Oct 30th, 2017.

Derek, nor any peers, have made any analyst calls on VNDA in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30